Skip to main content
SENORES PHARMACEUTICALS LIMITED logo

SENORES PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · SENORES ISIN · INE0RB801010 LEI · 984500FQ4CDFAFBBD763 BSE.NS Manufacturing
Open in API
Filings indexed 182 across all filing types
Latest filing 2026-01-31 Declaration of Voting R…
Country IN India
Listing BSE.NS SENORES

About SENORES PHARMACEUTICALS LIMITED

https://senorespharma.com/

Senores Pharmaceuticals Limited is an R&D-driven pharmaceutical organization specializing in the development, manufacturing, and commercialization of complex generic formulations. The company focuses on niche therapeutic segments and specialty products, including oral solids, liquids, and topicals, with a significant emphasis on complex injectables and ophthalmic solutions. Senores leverages its advanced research capabilities to address unmet medical needs in highly regulated global markets, particularly the United States. Its business model integrates end-to-end capabilities from product identification and formulation development to regulatory filing and global distribution. The company is committed to delivering high-quality, affordable healthcare solutions through strategic partnerships and a robust pipeline of value-added medicines designed to improve patient outcomes in specialized clinical areas.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is an intimation to the stock exchanges under SEBI and Companies Act regulations, providing consolidated Scrutinizer’s Report and detailed voting results for resolutions passed at the Extra-Ordinary General Meeting. It constitutes an official declaration of shareholder voting results. Therefore, it matches the definition of Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-01-31 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is titled 'Proceedings of the Extra-Ordinary General Meeting of the Company held on January 31, 2026' and details the conduct and discussions of the EGM, including attendance, resolutions proposed, voting procedures, and meeting conclusion. It is a detailed record of the meeting proceedings rather than just an announcement or voting results. The document is over 7,000 characters, indicating substantive content. It does not contain financial statements or quarterly results, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a voting results declaration alone, as it includes the full proceedings. Therefore, the document fits best under AGM Information (AGM-R), which includes presentations and materials shared during general meetings, including EGMs. Confidence is high given the detailed meeting content and regulatory references.
2026-01-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Q3FY26 of Senores Pharmaceuticals Limited. It includes management's opening remarks, financial performance details for the quarter and nine months, segmental performance, acquisition updates, and a Q&A session. The text explicitly mentions it is a transcript of the earnings call, with detailed financial data and operational performance discussed. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is about 15,000 characters long, contains substantive financial data and analysis, and is not merely an announcement or summary. Therefore, the correct classification is CT with high confidence.
2026-01-27 English
Copy of Newspaper Publication
Earnings Release Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE Limited and National Stock Exchange of India Limited) regarding the publication of extracts of unaudited financial results for the quarter and nine months ended December 31, 2025. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulations 30 and 47, which pertain to disclosure and publication of financial results. The document includes newspaper publication extracts of unaudited standalone and consolidated financial results, indicating it is an announcement of financial results rather than the full financial report itself. The document length is about 15,000 characters, but the content is primarily an announcement and includes newspaper extracts, not a comprehensive financial report with detailed financial statements and analysis. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. 9M 2026
2026-01-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing them about the audio recordings of an Earnings Conference Call held on January 20, 2026, regarding the un-audited financial results for the quarter and nine months ended December 31, 2025. It mentions compliance with SEBI regulations and provides a weblink to the audio recording. The document does not contain the transcript or detailed financial data itself, but rather is an announcement about the availability of the earnings call recording. The document length is short (2187 characters), and it serves as a notification rather than the full call transcript or financial report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and notification about the earnings call recording, not the full Call Transcript (CT) or Earnings Release (ER).
2026-01-20 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a submission to stock exchanges (BSE and NSE) regarding the statement of deviation or variation in utilization of funds raised through an Initial Public Offer (IPO) for the quarter ended December 31, 2025. It references compliance with SEBI regulations and circulars related to listing obligations and disclosure requirements. The content focuses on confirming that there has been no deviation or variation in the use of IPO proceeds as per the prospectus. It includes a detailed table showing fund utilization against original objectives and amounts raised. The document is a regulatory compliance filing specifically about fund utilization deviations for a public issue, which aligns with the category of Regulatory Filings (RNS) as it does not constitute a full financial report, audit report, or other specific report types. It is not an announcement of a report publication but a substantive regulatory disclosure. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-01-20 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.